发酵工程教研室Brief Introduction

丰明乾
时间:2016-09-20

丰明乾 博士  教授  博士生导师

教育经历

1993.9-1997.7 西北农林科技大学 农学系 作物遗传育种 农学学士学位

1997.9-2000.7 西北农林科技大学 生命科学技术学院 生物化学与分子生物学 理学硕士学位

2005.9-2008.7 南京大学 生命科学院 生物学 理学博士学位

 

科研与学术工作经历

2000.7-2005.9 华中农业大学生命科学技术学院 讲师 

2008.10-2015.11 美国NIH 博士后,助理研究员(Research Fellow

2011.12-现在 华中农业大学生命科学技术学院 教授

 

研究方向

抗体工程,肿瘤免疫学,病毒免疫学

 

代表性研究成果

论文

1.  Gao W, Tang Z, Zhang YF, Feng M, Qian M, Dimitrov DS, Ho M. Immunotoxin targeting glypican-3 regresses liver cancer via dual inhibition of Wnt signalling and protein synthesis. Nat Commun. 2015, 6:6536

2.  Feng M, Gao W, Wang R, Chen W, Man Y, Fig WD, Wang X, Dimitrov DS, and Ho M. Therapeutically targeting glypican-3 via a conformation-specific single-domain antibody in hepatocellular carcinoma. Proc Nat Sci Acad USA. 2013, 110:E1083-91.

3. Feng M, Ho M. Glypican-3 antibodies: a new therapeutic target for liver cancer. FEBS Lett. 2014, 588:377-82.

4.  Gao W, Kim H, Feng M, Phung Y, Xavier CP, Rubin JS, Ho M. Inactivation of Wnt signaling by a human  antibody that recognizes the heparan sulfate chains of glypican-3 for liver cancer therapy. Hepatology, 2014, 60:576-87

5.  Tang Z, Feng M, Gao W, Phung Y, Chen W, Chaudhary A, St Croix B, Qian M, Dimitrov DS, and Ho M.  A human single-domain antibody elicits potent anti-tumor activity by targeting an epitope in mesothelin close to the cancer cell surface. Mol Cancer Ther, 2013, 12: 416-26.

6.   Feng M., Kim H., Phung Y., and Ho M. Recombinant soluble glypican 3 protein inhibits the growth of hepatocellular carcinoma in vitro. Int J Cancer, 2011, 128: 2246-2247.

7.   Feng M., Zhang J., Anver M, Hassan R., and Ho M. In vivo imaging of human malignant mesothelioma grown orthotopically in the peritoneal cavity of nude mice. J Cancer, 2011, 2: 123-131.

8.   Ho M., Feng M., Fisher R.J., Rader C., and Pastan I. A novel high affinity human monoclonal antibody to mesothelin. Int J Cancer., 2011, 128: 2020-2030.

9.  Xiang X, Feng M, Felder M, Connor JP, Man YG, Patankar MS, and Ho M. HN125: A Novel Immunoadhesin Targeting MUC16 with Potential for Cancer Therapy. J Cancer, 2011, 2:280-91.

10.  Xiang X., Phung Y., Feng M., Nagashima K., Zhang J., Broaddus V.C., Hassan R., FitzGerald D., and Ho M.  The development and characterization of a human mesothelioma in vitro 3D model to investigate immunotoxin therapy. Plos one, 2011, 6: e14640.

11.  Yu L., Feng M., Kim H., Phung Y., Kleiner D.E., Gores G..J., Qian M., Wang X.W., and Ho M.  Mesothelin as a potential therapeutic target in human cholangiocarcinoma. J Cancer,2010, 1:141-149.  

授权专利

1. Human monoclonal antibodies specific for glypican-3 and use thereof. PCT application no. PCT/US2012/034186; International filling date 19/Apr/2012. Inventors: Ho M,Feng M, Gao W, Kim H, and Dimiter D.

2. Mesothelin antibodies and methods for eliciting potent antitumor activity. U.S. PCT/US2013/059883.  Inventors: Ho M, Pastan I, Dimitrov DS, Tang Z, Feng M, and Gao W

 

主讲课程

免疫学

 

研究生招生专业

生物化学与分子生物学

 

联系方式

实验室电话:027-87282669

电子邮箱:fengmingqian@mail.hzau.edu.cn

办公地点:第一综合楼A519

 

实验室介绍及网址:

 

中国·湖北·武汉 南湖狮子山街一号430070 Tel:+86-27-87282101 Fax:+86-27-87282469
CopyRight©2001-2010 华中农业大学生命科学技术学院 版权所有; E-mail:bio@mail.hzau.edu.cn 技术支持:现代教育技术中心